Regulus Therapeutics Inc (RGLS)
2.65
-0.04
(-1.49%)
USD |
NASDAQ |
May 03, 16:00
2.65
0.00 (0.00%)
After-Hours: 20:00
Regulus Therapeutics Accounts Payable (Quarterly): 0.204M for Dec. 31, 2023
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 0.204M |
September 30, 2023 | 0.599M |
June 30, 2023 | 0.362M |
March 31, 2023 | 0.581M |
December 31, 2022 | 0.175M |
September 30, 2022 | 0.796M |
June 30, 2022 | 0.595M |
March 31, 2022 | 0.625M |
December 31, 2021 | 0.285M |
September 30, 2021 | 0.586M |
June 30, 2021 | 1.393M |
March 31, 2021 | 0.81M |
December 31, 2020 | 0.535M |
September 30, 2020 | 1.102M |
June 30, 2020 | 1.024M |
March 31, 2020 | 1.03M |
December 31, 2019 | 1.321M |
September 30, 2019 | 1.521M |
June 30, 2019 | 1.602M |
March 31, 2019 | 2.65M |
December 31, 2018 | 1.714M |
September 30, 2018 | 1.235M |
June 30, 2018 | 5.468M |
March 31, 2018 | 4.396M |
Date | Value |
---|---|
December 31, 2017 | 5.743M |
September 30, 2017 | 5.229M |
June 30, 2017 | 4.901M |
March 31, 2017 | 4.509M |
December 31, 2016 | 5.84M |
September 30, 2016 | 5.724M |
June 30, 2016 | 3.504M |
March 31, 2016 | 3.622M |
December 31, 2015 | 2.717M |
September 30, 2015 | 3.392M |
June 30, 2015 | 2.407M |
March 31, 2015 | 2.677M |
December 31, 2014 | 2.188M |
September 30, 2014 | 2.642M |
June 30, 2014 | 3.018M |
March 31, 2014 | 2.691M |
December 31, 2013 | 1.172M |
September 30, 2013 | 1.14M |
June 30, 2013 | 1.028M |
March 31, 2013 | 0.398M |
December 31, 2012 | 0.311M |
September 30, 2012 | 0.649M |
June 30, 2012 | 0.762M |
December 31, 2011 | 0.501M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
0.175M
Minimum
Dec 2022
1.602M
Maximum
Jun 2019
0.7972M
Average
0.625M
Median
Mar 2022
Accounts Payable (Quarterly) Benchmarks
ACADIA Pharmaceuticals Inc | 17.54M |
ADMA Biologics Inc | 15.66M |
FibroGen Inc | 17.96M |
Protara Therapeutics Inc | 2.434M |
Amylyx Pharmaceuticals Inc | 22.06M |